Artelo Biosciences (ARTL) AI Stock Analysis

• Market Cap: $3.29M
• Dividend Yield: N/A
• Average Volume (3M): 89.20K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.60
• Revenue Growth: N/A
• EPS Growth: -22.52%
• Country: US
• Employees: 6
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -3.97
• Shares Outstanding: 2,018,746
• 10 Day Avg. Volume: 70,584
• 30 Day Avg. Volume: 89,202
• PEG Ratio: 0.73
• Price to Book (P/B): 7.17
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.45
• Enterprise Value/Market Cap: 0.66
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -0.18
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 43 Neutral
• Price Target: $1.50 ▲(20.97% Upside)

The score is primarily held down by very weak financial performance (no revenue, widening losses, ongoing cash burn) and heightened balance-sheet/listing risk (negative equity and Nasdaq compliance/delisting concerns). Technicals are only neutral-to-mixed and valuation offers limited support due to negative earnings and no dividend yield data.

Positive Factors

Positive Phase 2 interim data for ART27.13

Durable clinical proof-of-concept: interim CAReS Phase 2 data showed meaningful weight and lean-mass gains, improved activity, and a favorable safety profile. These outcomes address an unmet need, strengthen the case for partnering/registrational paths, and materially de-risks commercial potential.

Peer‑reviewed publications validating mechanisms

Independent peer-reviewed preclinical data for SBFI103 and other FABP programs provide mechanistic validation of Artelo’s approach. Scientific reproducibility strengthens regulatory and partner confidence, supports broader indication exploration, and underpins durable R&D value beyond short-term trial noise.

Completed strategic financing agreements

Ability to secure convertible notes and warrants from investors and insiders demonstrates ongoing access to committed capital and stakeholder support. This financing, while modest, improves near-term runway, helps sustain clinical programs, and signals investor willingness to back development execution.

Negative Factors

Zero revenue with persistent cash burn

Structural weakness: the company generates no product revenue and posts widening net losses and steady operating cash outflows. Negative stockholders’ equity and ongoing burn materially weaken financial flexibility, increasing dependency on external capital and raising solvency and dilution risk over the medium term.

Nasdaq listing compliance and delisting risk

A Nasdaq delist determination is a significant structural threat to liquidity and access to capital. Even with an appeal pending, unresolved compliance undermines market confidence, could constrain future financing or partnerships, and creates persistent operational and governance uncertainty.

Heavy reliance on external financings and dilution risk

Durable funding vulnerability: without commercial revenue, the company repeatedly taps equity and convertible instruments to fund R&D. Ongoing offerings and financings imply continual dilution risk and make program progress contingent on capital-market access, which can limit strategic flexibility.

Artelo Biosciences Business Overview & Revenue Model

Company Description

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. Artelo Biosciences, Inc. has research collaboration with Trinity College Dublin to investigate ART27.13 for the treatment of cancer cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

How the Company Makes Money

Artelo Biosciences generates revenue primarily through the development and potential commercialization of its proprietary drug candidates. The company's revenue model is largely based on achieving clinical and regulatory milestones that can attract licensing deals or partnerships with larger pharmaceutical companies. These partnerships may result in upfront payments, milestone payments, and royalties on sales of successfully commercialized products. Artelo may also seek government grants or research funding to support its development programs. As a company focused on drug development, its earnings are contingent on successful clinical trials, regulatory approvals, and market adoption of its therapies.

Artelo Biosciences Financial Statement Overview

Summary

Very weak fundamentals: no revenue, widening TTM net loss (~$12.5M vs. ~$9.8M in 2024), and persistent cash burn (TTM operating/free cash flow about -$8.2M). Balance-sheet risk is elevated with stockholders’ equity turning negative in TTM (~-$0.6M), increasing financing and solvency/dilution concerns despite modest absolute debt (~$1.0M).

Income Statement

ARTL shows no revenue across the provided periods, while losses remain sizable. TTM (Trailing-Twelve-Months) net loss widened to about $12.5M versus ~$9.8M in 2024, indicating higher spend and a weaker earnings trajectory. With no gross profit and continued negative operating results, profitability is entirely dependent on future commercialization or funding rather than current operations.

Balance Sheet

The balance sheet weakened materially: stockholders’ equity moved from positive levels in prior annual periods to negative in TTM (Trailing-Twelve-Months) (about -$0.6M), a major red flag for financial flexibility and dilution/solvency risk. Debt remains relatively small in absolute dollars (~$1.0M TTM), but negative equity makes leverage metrics unfavorable and reduces the cushion available to absorb ongoing losses.

Cash Flow

Cash burn is persistent but relatively steady: operating and free cash flow were about -$8.2M in TTM (Trailing-Twelve-Months) versus -$8.35M in 2024. The company’s cash outflow broadly tracks its net loss (free cash flow to net income ~1.0), suggesting losses are not being masked by large non-cash addbacks, but it also highlights that funding needs are ongoing without offsetting cash generation.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00	0.00
EBITDA	-12.35M	-10.11M	-9.93M	-10.08M	-7.44M	-4.69M
Net Income	-12.49M	-9.83M	-9.29M	-10.08M	-7.44M	-4.66M
Balance Sheet
Total Assets	4.27M	4.70M	13.04M	20.42M	12.63M	4.38M
Cash, Cash Equivalents and Short-Term Investments	1.72M	2.34M	10.43M	17.53M	10.06M	2.14M
Total Debt	954.00K	104.00K	23.00K	63.00K	95.00K	0.00
Total Liabilities	4.90M	1.84M	1.29M	1.02M	593.00K	502.18K
Stockholders Equity	-633.00K	2.86M	11.75M	19.40M	12.04M	3.87M
Cash Flow
Free Cash Flow	-8.18M	-8.35M	-8.21M	-8.01M	-6.14M	-4.35M
Operating Cash Flow	-8.18M	-8.35M	-8.21M	-8.01M	-6.14M	-4.35M
Investing Cash Flow	250.00K	7.77M	3.51M	2.96M	-3.44M	0.00
Financing Cash Flow	5.32M	112.00K	567.00K	0.00	14.11M	1.98M

Artelo Biosciences Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.24
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ARTL, the sentiment is Negative. The current price of 1.24 is below the 20-day moving average (MA) of 1.63, below the 50-day MA of 1.65, and below the 200-day MA of 5.85, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 42.51 is Neutral, neither overbought nor oversold. The STOCH value of 24.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ARTL.

Artelo Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TOVX	45 Neutral	$6.35M	-0.03	-166.96%	―	―	83.25%
ARTL	43 Neutral	$3.29M	-0.07	-436.14%	―	―	-22.52%
ENVB	42 Neutral	$4.05M	-0.03	-262.78%	―	―	79.45%
BDRX	41 Neutral	$1.05M	-0.02	-60.37%	―	-100.00%	86.75%
INDP	41 Neutral	$4.51M	-0.06	-317.98%	―	―	34.57%

Artelo Biosciences Corporate Events

Artelo Biosciences Shareholders Back Board, Pay and Auditor

On January 30, 2026, Artelo Biosciences reconvened its previously adjourned Annual Meeting of Stockholders, achieving a quorum with approximately 50.4% of outstanding common shares represented. Shareholders re-elected Douglas Blayney, M.D., and Connie Matsui as Class II directors to serve until the 2028 annual meeting, approved on an advisory basis the executive compensation package for the company’s named executive officers, and ratified Malone Bailey LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, thereby confirming support for current board composition, pay practices, and audit oversight.

The most recent analyst rating on (ARTL) stock is a Sell with a $1.50 price target. To see the full list of analyst forecasts on Artelo Biosciences stock, see the ARTL Stock Forecast page.

Artelo Biosciences faces new Nasdaq compliance challenges

Artelo Biosciences convened but then adjourned its 2025 annual meeting of stockholders on December 31, 2025 without conducting any business due to a lack of quorum, and plans to reconvene the meeting on January 30, 2026 to allow more time for shareholders to vote on existing proposals and the ratification of its independent auditor for the 2026 fiscal year. After notifying Nasdaq that the annual meeting had been adjourned, the company received a notice on January 14, 2026 stating it was not in compliance with Nasdaq’s requirement to hold an annual meeting within one year of fiscal year-end, which may serve as an additional basis for delisting alongside its previously disclosed shortfall in minimum stockholders’ equity; while the notice does not immediately affect trading of its shares, the company has presented a plan to regain compliance to a Nasdaq hearing panel, though there is no assurance its efforts will succeed.

The most recent analyst rating on (ARTL) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Artelo Biosciences stock, see the ARTL Stock Forecast page.

Artelo Biosciences Adjourns and Reschedules 2025 Annual Meeting

On December 31, 2025, Artelo Biosciences, Inc. convened but immediately adjourned its 2025 annual meeting of stockholders without conducting any business because it lacked a quorum of votes. The annual meeting is now scheduled to reconvene virtually on January 30, 2026, with the same record date of December 10, 2025, and previously submitted proxies still valid unless revoked. The company also plans to add a new proposal for shareholders to ratify the appointment of Malone Bailey LLP as independent auditor for the fiscal year ending December 31, 2026, while otherwise keeping the existing slate of proposals unchanged, a procedural step that may be important for governance continuity and auditor oversight but does not alter the company’s operational outlook.

The most recent analyst rating on (ARTL) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on Artelo Biosciences stock, see the ARTL Stock Forecast page.

Artelo Biosciences Appeals Nasdaq Delisting Decision

On November 19, 2025, Artelo Biosciences received a delist determination letter from Nasdaq due to non-compliance with Listing Rule 5550(b)(1), which requires maintaining stockholders’ equity of at least $2,500,000. Despite submitting plans to regain compliance, the company failed to raise the necessary capital. Artelo intends to appeal the decision to prevent delisting, allowing its stock to continue trading under the symbol ‘ARTL’ while the appeal is pending.

The most recent analyst rating on (ARTL) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Artelo Biosciences stock, see the ARTL Stock Forecast page.

Artelo Biosciences Revises Bylaws, Alters Governance Structure

On November 10, 2025, Artelo Biosciences, Inc. announced changes to its bylaws, impacting the governance structure of the company. The amendments include the elimination of stockholders’ rights to fill board vacancies and the election of directors by a plurality of votes at stockholder meetings, potentially affecting shareholder influence and corporate governance dynamics.

The most recent analyst rating on (ARTL) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Artelo Biosciences stock, see the ARTL Stock Forecast page.

Artelo Biosciences Strengthens Financial Position with New Agreement

On October 28, 2025, Artelo Biosciences entered into a Subscription Agreement with certain investors, resulting in the issuance and sale of convertible notes and warrants. The transaction involved an aggregate principal amount of $690,154.69 in notes and warrants to purchase 438,182 shares of common stock. This strategic move aims to strengthen the company’s financial position, with implications for its market operations and stakeholder interests, as it involves key directors and officers participating in the offering.

The most recent analyst rating on (ARTL) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Artelo Biosciences stock, see the ARTL Stock Forecast page.